With seven new-indication or product approvals possibly ahead through 2018, Alexion Pharmaceuticals Inc. should have no problem using the priority review voucher gained via the FDA's clearance Friday of Strensiq (asfotase alfa) for perinatal-, infantile- and juvenile-onset bone disorder hypophosphatasia (HPP), a high-cost, breakthrough therapy that shouldn't feel any pain during this election year's storm over drug profiteering.